The week in pharma: action, reaction and insight – week to October 27, 2023

29 October 2023
tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

M&A news last week saw Swiss pharma giant Roche announce last Monday it had agreed to acquire Roivant company Telavant and its TL1A-directed antibody RVT-3101 for $7.1 billion. Among research news, Johnson & Johnson presented much awaited new data at the European Society of Medical Oncology (ESMO) on its lung cancer drug Rybrevant. And Japan’s Eisai and US Biotech Biogen released new data for a subcutaneous formulation of their Alzheimer’s disease drug Leqembi at an AD clinical trials conference. Also of note, US pharma major Eli Lilly gained approval from the US Food and Drug Administration (FDA) for its ulcerative colitis drug Omvoh.

Roche to gain gut disease drug in $7.1 billion deal for Roivant subsidiary

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology